A Phase 2 Open-Label, Single-Arm Study to Evaluate the Efficacy and Safety of the Combination of Niraparib and TSR-042 in Patients With Platinum Resistant Ovarian Cancer

Condition:   Platinum-resistant Ovarian Cancer Interventions:   Drug: Niraparib;   Drug: TSR-042 Sponsors:   Tesaro, Inc.;   Gynecologic Oncology Group Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials